Physician profile
Daxes M Banit
NPI 1225086903
$5,491,573.72
in general payments reported to CMS, 2019-2025
7 companies · $18.53 in 2025
The $18.53 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.56 · 2021: $476 · 2022: $5.1M · 2023: $392K · 2025: $18.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $392K · Entertainment: $18.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $391,624.59 |
| Entertainment | $18.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Products, INC. | $5,491,004.87 | 2022-2023 | Fibulink |
| Captiva Spine INC | $461.82 | 2021 | |
| Bioventus LLC | $55.00 | 2022 | |
| Djo, LLC | $19.56 | 2019 | |
| Overture Orthopaedics | $18.53 | 2025 | Overtureti |
| Boston Scientific Corporation | $13.94 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$6,164,898.88 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daxes Banit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.